Solbec has been undervalued for a while now. Cancer and psoriasis both successful in phase I trials and the company is moving towards phase II in both these multi-billion dollar markets. The drug has been shown to stimulate immunity towards cancer and preclinical studies continue in this area with results expected in a month or two. This only adds to the excitement building towards Coramsine. There is also growing interest from overseas and one would expect news of a partnership agreement with a big pharam sooner rather than later.
- Forums
- ASX - By Stock
- SBP
- solbec now 12cents
SBP
solbec pharmaceuticals limited
solbec now 12cents, page-2
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
Previous Video
Next Video
SPONSORED BY The Market Online